| scholarly article | Q13442814 |
| P50 | author | Priya S Kishnani | Q83248117 |
| Stephanie M DeArmey | Q130279271 | ||
| P2093 | author name string | Sara K. Pasquali | |
| Stephen Darty | |||
| Jennifer S. Li | |||
| Michael J. Campbell | |||
| Richard J. Ing | |||
| Raymond J. Kim | |||
| Piers C. A. Barker | |||
| P2860 | cites work | Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease | Q28277595 |
| Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease | Q30489156 | ||
| Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial | Q33941289 | ||
| A randomized study of alglucosidase alfa in late-onset Pompe's disease | Q34110220 | ||
| How we perform delayed enhancement imaging | Q35185413 | ||
| The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature | Q35191008 | ||
| Pompe disease in infants and children | Q35764507 | ||
| Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance | Q36492202 | ||
| Cardiac magnetic resonance in myocardial disease | Q36498834 | ||
| Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease | Q36730504 | ||
| Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants | Q37040458 | ||
| Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. | Q37046582 | ||
| Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease | Q37196681 | ||
| Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance | Q37248274 | ||
| Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications | Q37684390 | ||
| The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. | Q38509986 | ||
| Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. | Q38518827 | ||
| Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters | Q42657184 | ||
| A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease | Q44312356 | ||
| Anaesthetic management of infants with glycogen storage disease type II: a physiological approach | Q47579830 | ||
| Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial | Q47869064 | ||
| Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series | Q48587106 | ||
| Rapid evaluation of right and left ventricular function and mass using real-time true-FISP cine MR imaging without breath-hold: comparison with segmented true-FISP cine MR imaging with breath-hold. | Q51661854 | ||
| Electrocardiographic response to enzyme replacement therapy for Pompe disease. | Q51807688 | ||
| Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. | Q51943299 | ||
| A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. | Q52913556 | ||
| Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging | Q57750678 | ||
| Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy | Q58910153 | ||
| Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease | Q59383519 | ||
| Estimation of human myocardial mass with MR imaging | Q70062263 | ||
| MRI characterization of myocardial tissue in patients with Fabry's disease | Q79803239 | ||
| Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa | Q80273839 | ||
| Fabry's disease presenting as ventricular tachycardia and left ventricular 'hypertrophy' | Q81304962 | ||
| Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue | Q81310937 | ||
| Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy | Q83297082 | ||
| Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy | Q83388755 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme replacement therapy | Q916766 |
| cardiac magnetic resonance imaging | Q5038325 | ||
| P304 | page(s) | 332-337 | |
| P577 | publication date | 2010-07-23 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy | |
| P478 | volume | 101 |
| Q37976637 | Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques |
| Q36590950 | Cardiac Pathology in Glycogen Storage Disease Type III |
| Q26767019 | Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population. |
| Q26775739 | Delayed Myocardial Enhancement in Cardiac Magnetic Resonance Imaging |
| Q26829408 | Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI |
| Q62075654 | Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI |
| Q38966998 | Left ventricular mass and systolic function in children with chronic kidney disease-comparing echocardiography with cardiac magnetic resonance imaging. |
| Q38782767 | Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of Echoc |
| Q38344492 | Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis |
| Q38800985 | Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel |
| Q48681869 | Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease |
| Q30573752 | The emerging phenotype of long-term survivors with infantile Pompe disease. |
| Q30528799 | Unusual cardiac "masses" in a newborn with infantile pompe disease |
Search more.